The Comprehensive Center for Fanconi Anemia & The Cytogenetic Facility

Amifostine

A Phase I Study of Amifostine in Patients with Fanconi Anemia

Trial Site: Children's Hospital, Boston Investigators: W. Nicholas Haining, M.D. and Eva C. Guinan, M.D.

Expected Accrual:
Approximately 20 patients

Eligibility:

Exclusion:

Study: Open label phase I study of amifostine given intravenously at one of three doses three times a week for 9 doses, followed by three week observation period consisting of weekly CBC's.

Endpoints:

Contact:
W. Nicholas Haining, M.D.
Dana Farber Cancer Institute
44 Binney Street
Boston, MA 02115 (617) 632 5293